Table 2.
Subject characteristics.
| Group | No. of patients | Stage |
Gender, |
Age, years, |
||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | Unk. | % female | median (range) | ||
| Breast cancer | 8 | - | 6 | 2 | - | - | 88% | 57 (51–68) |
| Colon cancer | 7 | - | 3 | 4 | - | - | 86% | 63 (49–72) |
| Gastric cancer | 7 | 3 | 1 | 2 | 1 | - | 43% | 65 (58–81)⁎ |
| Malignant melanoma | 4 | 1 | 2 | 1 | - | - | 25% | 58 (43–64) |
| NSCLC | 10 | 4 | 2 | 3 | - | 1 | 30% | 58 (47–80) |
| SCLC | 7 | 1 | 2 | 3 | 1 | - | 29% | 58 (46–82) |
| Ovarian cancer | 8 | 1 | 2 | 5 | - | - | 100% | 57 (37–74) |
| Pancreas cancer | 4 | 1 | - | 1 | - | 2 | 75% | 66.5 (56–69) |
| Prostate cancer | 10 | 1 | 9 | - | - | - | 0% | 63 (57–72)⁎ |
| Healthy controls | 13 | - | - | - | - | - | 23% | 53 (39–63) |
⁎
Significantly different (P < .05) from healthy controls (Kruskal-Wallis test adjusted with Dunn's test for comparing each cancer group to the healthy controls). NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer.